Results 21 to 30 of about 1,692 (164)
European Medical Journal Urology, 2020 Objective: Vaginal atrophy, vulvovaginal dystrophy, and stress urinary incontinence (SUI), common conditions in women, have detrimental effects on quality of life.
Laura Stark +5 more
doaj +1 more source
Medical and Health Science Journal, 2020 Background : Vulvovaginal atrophy is a condition that often occurs in menopausal women due to Estrogen decreased. Prasterone (DHEA) is a steroid hormone that can be converted into Estrogen in the target tissue.
Zettira Maulida Prasha, Hari Paraton
doaj +1 more source
Гинекология, 2023 Hypoestrogenism associated with menopause has a strong negative effect on the condition of the vagina and urinary tract, and often leads to the development of genitourinary menopausal syndrome, significantly disrupting the quality of life of women ...
Liana Z. Ziganshina +3 more
doaj +1 more source
The therapeutic effect of dehydroepiandrosterone (DHEA) on vulvovaginal atrophy
Pharmacological Research, 2021 Vulvovaginal atrophy (VVA) is a chronic disease that mostly occurs in postmenopausal women. After menopause, insufficient sex hormones affect the anatomy of the vagina and cause drastic physiological changes. The main histopathological studies of VVA show that postmenopausal estrogen deficiency can lead to the increase of intermediate/parabasal cells ...
Jing, Wang, Ling, Wang
openaire +2 more sources
Women’s Sexual Dysfunctions Following Stem Cell Transplant and the Impact on Couple Relationship
Life, 2023 Stem cell transplant proved its efficacy in increasing the survival rate among young patients diagnosed with hematological malignancies. A transplant conditioning regimen is particularly destructive on the genital system, often determining premature ...
Mihaela Plotogea +11 more
doaj +1 more source
Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy
Gynecological Endocrinology, 2021 It is estimated that 50% of women will suffer a severe form of vulvovaginal atrophy (VVA) related to menopause. Equally, young women may temporarily present this clinical problem while receiving various pharmacological or endocrine treatments or radiotherapy.To determine clinical and diagnostic exams required to confirm the presence of VVA (also ...
Faustino R. Pérez-López +5 more
openaire +2 more sources
Gynecological Endocrinology, 2021 To develop a best practice document for the management of postmenopausal vulvovaginal atrophy (VVA).Literature review carried out using clinical terms, treatments or interventions and comorbidity related to VVA.There is a wide variety of interventions that may produce temporal benefits for VVA.
Faustino R. Pérez-López +5 more
openaire +2 more sources
Ospemifene: A Novel Option for the Treatment of Vulvovaginal Atrophy. [PDF]
J Menopausal Med, 2017 Ospemifene-a third-generation selective estrogen receptor modulator approved by the Food and Drug Administration in 2013-is an oral medication for the treatment of dyspareunia. In postmenopausal women with vulvovaginal atrophy, ospemifene significantly improves the structure and pH levels of the vagina, reducing dyspareunia.
Shin JJ, Kim SK, Lee JR, Suh CS.
europepmc +4 more sources
Vulvovaginal atrophy in the peri- and post-menopause: relevance and impact on quality of life [PDF]
Гинекология, 2022 Vulvovaginal atrophy (VVA) is detected in more than 50% of postmenopausal women, and at 4049 years of age, 15-19% of women have relevant signs. Atrophic changes in the female urogenital system are associated with hypoestrogenism, which results in the ...
Mekan R. Orazov +5 more
doaj +1 more source
Кубанский научный медицинский вестникBackground. Vulvovaginal atrophy is a chronic, progressive condition associated with estrogen deficiency. While involutional changes are well-documented, the relationship between the vaginal microbiota and the local immune response in vulvovaginal ...
M. I. Biryukova +2 more
doaj +1 more source